Area of research
Genetics · Neurology
Research interest
Research interests include Glioma Diagnosis and Treatment, Neuroblastoma Research and Treatments, Meningioma and schwannoma management, and Cancer, Hypoxia, and Metabolism.
Back to square one: Treatment for ependymoma in the post-ACNS0831 era.
Balancing Risk, Benefit, and Reality: Navigating Early Phase Studies in Pediatric Diffuse Midline Glioma.
Physical Therapy Surveillance in Children with Acute Lymphoblastic Leukemia: A Quality Improvement Initiative.
Parent Perspectives on Physical Therapy for Their Child with Acute Lymphoblastic Leukemia: <i>The Light at the End of the Tunnel</i>.
Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-mutant: An International Multi-Institutional Study.
Deciphering UBE4B phosphorylation dynamics: a key mechanism in p53 accumulation and cancer cell response to DNA damage.
The 2021 WHO classification of tumors of the central nervous system: Responding to the challenge in low- and middle-income countries.
The DLX/Notch axis is necessary for spatiotemporal regulation of neural cell fate
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Multidimensional, integrative profiling identifies BCL2L1 methylation as a predictor of MCL1 dependency in pediatric malignancies
“Like a Clinical Nurse Consultant in Your Pocket.” Implementing a Co-Designed Smartphone App Following Treatment for Pediatric Cancer: A Feasibility Study. (Preprint)
Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Precision-guided treatment in high-risk pediatric cancers.
GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma
PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma.
Comments and Controversies in Oncology: The Tribulations of Trials Developing ONC201
The Landscape of Pediatric High-Grade Gliomas: The Virtues and Pitfalls of Pre-Clinical Models.
A paradigm shift in how we treat pediatric low-grade glioma-Targeting the molecular drivers.
"If you build it, they will come": the convergence of funding, research and collaboration in paediatric brain cancer clinical trials.
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
RNA cytosine methyltransferase NSUN5 promotes protein synthesis and tumorigenic phenotypes in glioblastoma.
Implementation of DNA Methylation Array Profiling in Pediatric Central Nervous System Tumors
HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma.
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Genetics · Neurology →